TY - JOUR AU - Sehar Bashir AU - Asif Loya AU - Sana Tabish AU - Sajid Mushtaq AU - Usman Hassan AU - Mudassir Hussain PY - 2021/01/11 Y2 - 2024/03/29 TI - Expression of B-cell Lymphoma 2 (BCL-2) in Breast Cancer JF - Journal of Cancer & Allied Specialties JA - J Cancer Allied Spec VL - 7 IS - 1 SE - Original Research Article DO - 10.37029/jcas.v7i1.369 UR - https://journals.sfu.ca/jcas/index.php/jcas/article/view/369 AB - Introduction: Immunohistochemical expression of B-cell lymphoma 2 (BCL-2) is seen variably in invasive ductal carcinoma. This study was conducted to determine the frequency of BCL-2 expression in different histologic grades of invasive ductal carcinoma. Materials and Methods: A cross-sectional study was conducted in the Department of Pathology at Shaukat Khanum Memorial Cancer Hospital and Research Centre, Pakistan, on subjects with invasive ductal carcinoma of various histologic grades. Immunohistochemistry was done using the BCL-2 antibody in all cases. The frequency of BCL-2 positive cases in different histologic grades was noted. Post-stratification, the chi-square test was applied. A p-value ≤ 0.05 was considered significant. Results: All 52 subjects were females (100%) with a mean age of 47.58 ± 1.43 years. BCL-2 expression was observed in 28 (53.85 %) subjects with breast cancer. Out of 33 participants with grade III, 13 (39.39 %) participants were positive for BCL-2 expression. Among 18 subjects with grade II, 14 (77.78 %) subjects were positive for BCL-2 expression. Reduced frequency of BCL-2 expression was observed with increasing histologic grade (i.e., more in low-grade tumors and less in grade III), but the difference was statistically not significant. Conclusion: A differential expression of BCL-2 was observed across different grades of invasive ductal carcinoma. However, the difference was not statistically significant. ER -